The dispute involved payments made by Ranbaxy, now merged with Sun Pharmaceutical Industries Ltd, to Teva Israel under a 2011 settlement relating to the US launch of generic atorvastatin.

See all 313 in Finance →

By

Leave a Reply

Your email address will not be published. Required fields are marked *